Valuation: Insmed Incorporated

Market Cap 23.18B 20.39B 18.95B 17.4B 32.66B 2,238B 33.21B 225B 87.89B 1,097B 86.99B 85.12B 3,796B P/E 2026 *
-41.9x
P/E 2027 * 212x
Enterprise Value 22.61B 19.9B 18.49B 16.98B 31.86B 2,183B 32.4B 220B 85.76B 1,070B 84.88B 83.05B 3,704B EV / Sales 2026 *
13.3x
EV / Sales 2027 * 7.99x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insmed Incorporated

1 day-0.46%
1 week-1.29%
Current month+0.28%
1 month+3.34%
3 months-20.90%
6 months-31.55%
Current year-38.57%
1 week 105.09
Extreme 105.09
109.99
1 month 102.59
Extreme 102.59
119.54
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 20.28
Extreme 20.28
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
7/9/26 Fiscal year

Chief Executive Officer

32,097 0.0148%
7/6/26 Fiscal year

Chief Technology Officer

36,906 0.0170%
6/25/26 Fiscal year

Chief Executive Officer

64,194 0.0296%
Change 5-day change 1-year change 3-year change Capi.($)
-0.46%-1.29%+3.28%+422.58% 23.18B
+0.93%+6.97%+62.83%+67.97% 57.28B
-1.92%+6.03%+43.68%+84.56% 54.99B
-2.97%-2.35%-22.03%-16.54% 22.59B
-0.36%+5.73%+30.99%-3.58% 20.46B
-1.34%+0.51%+25.02%-30.27% 17.56B
-1.44%+5.67%+32.54%+544.11% 15.67B
-1.30%-5.02%+165.62%+291.37% 14.46B
-0.50%-0.98%+23.62%+178.38% 13.92B
+0.21%-1.62%+82.01%+164.74% 12.55B
Average -0.92%+0.99%+44.76%+170.33% 25.27B
Weighted average by Cap. -0.82%+1.91%+43.21%+137.13%

Financials

2026 *2027 *
Net sales 1.7B 1.5B 1.39B 1.28B 2.4B 164B 2.44B 16.52B 6.45B 80.5B 6.38B 6.25B 279B 2.78B 2.44B 2.27B 2.08B 3.91B 268B 3.98B 26.96B 10.53B 131B 10.42B 10.2B 455B
Net income -561M -494M -459M -421M -791M -54.2B -804M -5.45B -2.13B -26.57B -2.11B -2.06B -91.94B 71.64M 63.03M 58.58M 53.79M 101M 6.92B 103M 696M 272M 3.39B 269M 263M 11.73B
Net Debt -563M -495M -460M -423M -793M -54.37B -807M -5.47B -2.14B -26.65B -2.11B -2.07B -92.22B -979M -861M -800M -735M -1.38B -94.49B -1.4B -9.5B -3.71B -46.32B -3.67B -3.59B -160B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-07-24 US$106.92 -0.46% 1,908,298
26-07-23 US$107.41 +0.72% 1,752,962
26-07-22 US$106.64 -1.82% 1,771,277
26-07-21 US$108.62 +1.50% 2,447,392
26-07-20 US$107.02 -1.20% 2,015,930
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
106.92USD
Average target price
196.18USD
Spread / Average Target
+83.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock